U.S., June 3 -- ClinicalTrials.gov registry received information related to the study (NCT07622004) titled 'Evaluate the Efficacy and Safety of INI101 Compared to BOTOX(R) in Subjects With Moderate to Severe Glabellar Lines.' on May 26.

Brief Summary: To evaluate the efficacy and safety of botulinum toxin type A for injection INI101 compared to BOTOX(R) in subjects with moderate to severe glabellar lines.

Study Start Date: May 27, 2021

Study Type: INTERVENTIONAL

Condition: Glabellar Lines

Intervention: DRUG: Botulinum Toxin Type A Injection [INI101]

Single administration, Day 0, 20 units

DRUG: Botulinum Toxin Type A Injection [Botox]

Single administration, Day 0, 20 units

Recruitment Status: COMPLETED

Sponsor: INIBIO Co., Ltd. ...